DSM Venturing Invests In Tianjin GreenBio
This article was originally published in PharmAsia News
Holland DSM Venturing has completed its initial investment in China that involves a $20 million share in Tianjin Green Biosciences Ltd. Co. The fund will be used to build China's largest polyhydroxyalkanoate production in Tianjin Economic - Technological Development Area, with construction to begin in the second quarter of this year. Targeted for operation in the beginning of 2009, the facility has the capacity to output 10,000 tonnes of PHA annually. DSM chose to invest in PHA for its use in the production of environment-friendly products. The company revealed that it has allocated €200 million for venture capital before 2012 and China will be one of its key investment areas. (Click here for more - Chinese Language)
You may also be interested in...
The China National Biotec Group has filed the first application in China for the broad use of a COVID-19 vaccine, days after the national regulatory agency released review guidelines for the conditional approval of such products.
More patent-related turbulence appears ahead for Novartis’s sacubitril/valsartan combination in India, with Torrent emerging as the new challenger. The companies are engaged in a legal battle and the Indian firm is also seeking a revocation of the patent on the star heart failure treatment.
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.